Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases
Who can join
As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.
- Age
- 18 Years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
- Compensation
- Not stated
Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.
What to expect
No one can promise a trial will help you personally — that is what the research is trying to find out.
What participation involves
Not stated in the study description — ask the study team about visits and procedures.
- Compensation
- Not stated
- Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
- Participants are monitored closely by the research team throughout the study.
- Some participants may receive access to an investigational treatment, which is still being studied.
- Your participation helps researchers learn whether this approach could help future patients.
About this study
A prospective, interventional study evaluating the safety of Y-90 TARE for tumor control of the right side and induction of left liver hypertrophy as part of a planned single-stage or two-stage hepatectomy for patients with CLM and insufficient FLR at the time of presentation.
Compensation is read from the study's own description and may be missing — always confirm with the study team.
Eligibility
Official eligibility criteria
Inclusion Criteria: * Borderline resectable unresectable (due to insufficient liver volume at presentation) colorectal liver metastases with potential curative intent, as determined by the surgeon and multidisciplinary team * Anticipated standardized FLR (sFLR) that would require right portal vein embolization (PVE) to increase the sFLR prior to either a single major hepatectomy, or prior to the second stage hepatectomy as part of a two-stage hepatectomy strategy, all in the setting of curative-intent resection(s). This evaluation will be documented in the clinical chart * Received at least four cycles (or two months) of chemotherapy * Willing, able and mentally competent to provide written informed consent * Medically and physically operable as determined by the surgeon Exclusion Criteria: * Extrahepatic disease that precludes intended curative intent treatment sequencing (treatable primary tumor and lung metastases allowed). "Treatable" is defined as having an intended future plan for local therapy (surgery, radiation, or ablation) as determined by the patient's medical oncologist and surgical oncologist * Projected sFLR before Y-90 of \<20% (starting with sFLR that is unrealistic for improvement to ≥30%) * Performance status limitations (Karnofsky \<80%, ECOG \>1) * Portal hypertension and/or cirrhosis * Starting total bilirubin \>1.3 mg/dL (except if patient has Gilbert's Disease) * CEA \>200 after 4 cycles of chemotherapy upon restaging visit * Clinical progression of disease on imaging and/or tumor marker after 4 cycles of chemotherapy that is clinically judged by surgical oncology and medical oncology to preclude surgical resection * Platelet count \<100,000/µL * Albumin \<3.5 g/dl * Symptomatic primary colon or rectal cancer (without pre-existing proximal diverting ostomy) * Pregnant or breast-feeding patient * Other medical or clinical contraindications to liver surgery * Non-English-speaking participants
Study sites (1)
TX
- M D Anderson Cancer Center · Houston, TX 77030Ching-Wei David Tzeng, MD · Study contactChing-Wei David Tzeng, MD · Principal investigatorMore trials in Houston